News About Expanesthetics

Expanesthetics raises additional $1.1 million

August 14, 2018 | Expanesthetics Press Release

Northern California pharmaceutical company Expanesthetics announces more than one million dollars in additional funding from existing shareholders. The funding will be used to continue to advance the company’s R&D initiatives and strengthen the company’s growing global collaborations. Expanesthetics is the global leader in the search for improved inhaled surgical anesthetics.

Back to top

Expanesthetics presents to biotech industry leaders at BIO 2018

June 6, 2018 | Expanesthetics Press Release

By becoming a Buzz of BIO finalist, Expanesthetics earned the opportunity to present to a large crowd of biotech leaders at the 2018 BIO International Convention in June at the Boston Convention Center. Attendees included venture funds, leading global pharmaceutical companies, and others with an interest in the future of anesthesia drug development from around the world. CEO Mark Holman hosted the presentation, focusing on the vision and goals of the company to bring a new generation of improved anesthetics to the market through a licensed screening technology. Click the headline for the full article.

Back to top

Expanesthetics Passes $2.25M Fundraising Hurdle

February 17, 2017

On its way to accelerating development of its analgesic and anesthetic programs, Expanesthetics announces the completion of an important fundraising target: $2.25M in seed funding. "This is just the start to a major multi-year campaign to bring brand new approaches to both general anesthesia and pain," said CEO Mark Holman. Holman continued, "The dozens of anesthesiologists who are participating investors in our company shows the market demand for major changes and the potential of our technology to meet that need."

Back to top